logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen Idec Posts Higher Q1 Profit; Ups 2013 Targets - Quick Facts

Biogen Idec Inc. (BIIB) reported an improvement in first-quarter 2013 GAAP net income to $426.75 million, or $1.79 a share, from $302.66 million, or $1.25 a share, a year earlier. According to non-GAAP basis, net income attributable to Biogen Idec was $469.4 million, or $1.97 a share, the company added. On average, 26 analysts polled by Thomson Reuters expected earnings per share of $1.61 for the quarter. Analysts' estimates typically exclude one-time items.

Quarterly total revenues of $1.42 billion, were 10% higher than $1.29 billion in the first quarter of 2012. Analysts estimated revenues of $1.42 billion for the quarter.

For full year 2013, the company now sees non-GAAP earnings per share between $7.80 and $7.90, GAAP earnings per share between $6.69 and $6.79, as well as revenue growth to be around 16% - 18%. Earlier Biogen expected fiscal 2013 adjusted earnings of $7.15 - $7.25 per share on projected revenue growth of about 10 percent. Analysts project annual earnings of $7.79 per share.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
So far this year, 23 novel drugs have already received FDA approval. Now let's take a look at the biotech stocks waiting to hear from the FDA in July. President Donald Trump has continued his assault on one of his favorite targets on Wednesday, lashing out at major media outlets in a series of posts on Twitter. Trump singled out the New York Times and the Washington Post in his tweets, describing the newspapers as "fake news." Christoph, born on-board a Spirit flight destined to Dallas from Fort Lauderdale airport, can celebrate all his forthcoming birthdays in life with a free travel on Spirit airline.
comments powered by Disqus
Follow RTT